HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysisM. Juliana McElrath, Danilo R. Casimiro, Stephen C. De Rosa et al.|The Lancet|2008Cited by 699
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded PhaseHana M. El Sahly, Jacqueline M. Miller, Lindsey R. Baden et al.|New England Journal of Medicine|2021Cited by 661
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical TrialDean Follmann, Lindsey R. Baden, Holly Janes et al.|Annals of Internal Medicine|2022Cited by 138
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trialShuying S. Li, Daniel E. Geraghty, Paul T. Edlefsen et al.|Journal of Clinical Investigation|2014Cited by 109
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trialDavid Benkeser, David C. Montefiori, Adrian B. McDermott et al.|Science Translational Medicine|2023Cited by 48